Italia - italiano - Ministero della Salute

le vet b.v. - ivermectina - ivermectina - 12 milligrammo/grammo, ivermectina - 12 mg/g - ivermectin

Italia - italiano - Ministero della Salute

eco animal health europe limited - ivermectina - ivermectina - 6 mg/g - ivermectin

Italia - italiano - Ministero della Salute

ceva salute animale s.p.a. - s-methoprene, fipronil - s-methoprene - 240 milligrammo (i); fipronil - 480 milligrammo (i), s-methoprene - 360 milligrammo (i); fipronil - 720 milligrammo (i), s-methoprene - 34 milligrammo (i); fipronil - 68 milligrammo (i), s-methoprene - 120 milligrammo (i); fipronil - 240 milligrammo (i), s-methoprene - 120 mg; fipronil - 240 mg, fipronil - 480 mg; s-methoprene - 240 mg, fipronil - 68 mg; s-methoprene - 34 mg, fipronil - 240 mg; s-methoprene - 120 mg, s-methoprene - 34 mg; fipronil - 68 mg, s-methoprene - 360 mg; fipronil - 720 mg, fipronil - 720 mg; s-methoprene - 360 mg, s-methoprene - 240 mg; fipronil - 480 mg, s-methoprene - 60 mg; fipronil - 120 mg - fipronil, combinations

Unione Europea - italiano - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - palifermin - mucosite - tutti gli altri prodotti terapeutici - kepivance è indicato per ridurre l'incidenza, la durata e la severità della mucosite orale in pazienti adulti con tumori ematologici ricezione radiochemioterapia mieloablativa associata con un'alta incidenza di mucosite grave e che richiedono autologo--cellule staminali emopoietiche supporto.

Unione Europea - italiano - EMA (European Medicines Agency)

roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - agenti antineoplastici - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq come monoterapia è indicato per il trattamento di pazienti adulti con carcinoma localmente avanzato o metastatico nsclc dopo una precedente chemioterapia. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq come monoterapia è indicato per il trattamento di pazienti adulti con carcinoma localmente avanzato o metastatico nsclc dopo una precedente chemioterapia. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.

Unione Europea - italiano - EMA (European Medicines Agency)

astellas pharma europe b.v. - enfortumab vedotin - carcinoma, transitional cell; urologic neoplasms - agenti antineoplastici - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor 1 or programmed death ligand 1 inhibitor.

Italia - italiano - Ministero della Salute

ceva sante' animale - s-methoprene, fipronil - fipronil - 68 milligrammo (i); s-methoprene - 34.02 milligrammo (i), s-methoprene - 360.4 milligrammo (i); fipronil - 720.8 milligrammo (i), s-methoprene - 239.7 milligrammo (i); fipronil - 479.4 milligrammo (i), s-methoprene - 119.85 milligrammo (i); fipronil - 239.7 milligrammo (i), fipronil - 479.4 milligrammo (i); s-methoprene - 239.7 milligrammo (i), fipronil - 120.7 mg; s-methoprene - 60.35 mg, s-methoprene - 119.85 mg; fipronil - 239.7 mg, fipronil - 68 mg; s-methoprene - 34.02 mg, fipronil - 720.8 mg; s-methoprene - 360.4 mg, s-methoprene - 34.02 mg; fipronil - 68 mg, fipronil - 479.4 mg; s-methoprene - 239.7 mg, fipronil - 239.7 mg; s-methoprene - 119.85 mg, s-methoprene - 60.35 mg; fipronil - 120.7 mg, s-methoprene - 360.4 mg; fipronil - 720.8 mg, s-methoprene - 239.7 mg; fipronil - 479.4 mg - fipronil, combinations

Italia - italiano - Ministero della Salute

alfamed s.a.s. - permetrina, fipronil - fipronil - 402.6 milligrammo (i); permetrina - 3597 milligrammo (i), permetrina - 2398 milligrammo (i); fipronil - 268.4 milligrammo (i), permetrina - 239.8 mg; fipronil - 26.84 mg, fipronil - 67.1 mg; permetrina - 599.5 mg, permetrina - 599.5 mg; fipronil - 67.1 mg, permetrina - 3597 mg; fipronil - 402.6 mg, fipronil - 402.6 mg; permetrina - 3597 mg, fipronil - 268.4 mg; permetrina - 2398 mg, permetrina - 2398 mg; fipronil - 268.4 mg, fipronil - 134.2 mg; permetrina - 1199 mg, permetrina - nd ; fipronil - 26.84 mg; permetrina - 239.8 mg, fipronil - 26.84 mg; permetrina - 239.8 mg, permetrina - 1199 mg; fipronil - 134.2 mg - permethrin, combinations

Italia - italiano - Ministero della Salute

alfamed s.a.s. - permetrina, fipronil - permetrina - 239.8 milligrammo (i); fipronil - 26.84 milligrammo (i), permetrina - 599.5 milligrammo (i); fipronil - 67.1 milligrammo (i), fipronil - 67.1 mg; permetrina - 599.5 mg, fipronil - 268.4 mg; permetrina - 2398 mg, permetrina - 1199 mg; fipronil - 134.2 mg, fipronil - 402.6 mg; permetrina - 3597 mg, permetrina - 3597 mg; fipronil - 402.6 mg, fipronil - 26.84 mg; permetrina - 239.8 mg, permetrina - 599.5 mg; fipronil - 67.1 mg - permethrin, combinations

Unione Europea - italiano - EMA (European Medicines Agency)

accord healthcare s.l.u. - leuprorelin mesilate - neoplasie prostatiche - terapia endocrina - camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.